ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.00%
US Dollar vs MXN
16.5813
-0.12%
Brent Oil
83.565
-0.04%
Bitcoin
67,125.87
1.46%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Biocept Inc (BIOC)

  7. Biocept Inc (BIOC) Noticias

BIOC

Biocept (BIOC)

Biocept Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:BIOC
FechaHoraFuenteTítuloSímboloCompañía
20/10/202305:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIOCBiocept Inc
21/09/202307:00Business WireEnrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal MetastasesNASDAQ:BIOCBiocept Inc
08/09/202307:00Business WireBiocept Signs CNSide™ Licensing Agreement with Plus TherapeuticsNASDAQ:BIOCBiocept Inc
05/09/202307:00Business WireBiocept to Participate in the H.C. Wainwright Global Investment ConferenceNASDAQ:BIOCBiocept Inc
25/08/202307:00Business WireBiocept to Hold Business Update Conference Call on August 30, 2023NASDAQ:BIOCBiocept Inc
14/08/202315:05Business WireBiocept Reports Second Quarter 2023 Financial ResultsNASDAQ:BIOCBiocept Inc
14/08/202307:00Business WireBiocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer ConferenceNASDAQ:BIOCBiocept Inc
13/07/202317:15Business WireBiocept Announces the Passing of Board Chair M. Faye WilsonNASDAQ:BIOCBiocept Inc
21/06/202315:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BIOCBiocept Inc
20/06/202318:10Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BIOCBiocept Inc
20/06/202315:15Business WireBiocept Names Antonino Morales as President and Chief Executive OfficerNASDAQ:BIOCBiocept Inc
14/06/202315:05Business WireBiocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023NASDAQ:BIOCBiocept Inc
05/06/202307:00Business WireScientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept’s CNSide™ Versus CytologyNASDAQ:BIOCBiocept Inc
25/05/202305:04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:BIOCBiocept Inc
24/05/202319:39Business WireBiocept Announces Pricing of $5.0 Million Underwritten Public OfferingNASDAQ:BIOCBiocept Inc
23/05/202307:18Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:BIOCBiocept Inc
17/05/202307:00Business WireBiocept Announces One-for-Thirty Reverse Stock SplitNASDAQ:BIOCBiocept Inc
10/05/202315:05Business WireBiocept Reports First Quarter 2023 Financial ResultsNASDAQ:BIOCBiocept Inc
21/04/202307:31Edgar (US Regulatory)Revised Proxy Soliciting Materials (definitive) (defr14a)NASDAQ:BIOCBiocept Inc
20/04/202315:07Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:BIOCBiocept Inc
17/04/202315:10Business WireBiocept Reports 2022 Financial ResultsNASDAQ:BIOCBiocept Inc
17/04/202315:04Edgar (US Regulatory)Amended Quarterly Report (10-q/a)NASDAQ:BIOCBiocept Inc
03/04/202307:01Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:BIOCBiocept Inc
24/03/202307:00Business WireEnrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal MetastasesNASDAQ:BIOCBiocept Inc
01/03/202307:00Business WireBiocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BIOCBiocept Inc
06/01/202305:55Business WireBiocept to Explore Strategic Alternatives and Implement Restructuring PlanNASDAQ:BIOCBiocept Inc
21/11/202215:12Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BIOCBiocept Inc
21/11/202215:05Business WireBiocept Reports Third Quarter 2022 Financial ResultsNASDAQ:BIOCBiocept Inc
18/11/202207:00Business WireBiocept Appoints Financial Executive Quyen Dao-Haddock to its Board of DirectorsNASDAQ:BIOCBiocept Inc
16/11/202207:00Business WireBiocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous SystemNASDAQ:BIOCBiocept Inc
 Showing the most relevant articles for your search:NASDAQ:BIOC

Su Consulta Reciente

NASDAQ
RNWWW
ReNew Energy Global
BOV
NUTR3M
NUTRIPLANT ON
NYSE
TIMB
TIM
BOV
SUZB3Q
SUZANO PAPEL ON
NASDAQ
ICG
Intchains
BOV
CASH3
Meliuz S.A ON
GATE
SANDUSD
Sandbox
BINA
ADABTC
Cardano
BOV
FHER3
FER HERINGER ON
ASX
ARU
Arafura Rare Earths
USOTC
PRMFF
Perimeter Solutions (PK)
LSE
PRV
Porvair
CXIO
SANDUSD
Sandbox
NYSE
TPR
Tapestry
NASDAQ
LYFT
Lyft
DGFX
MANAUSDT
Decentraland
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados